Non-Cash Royalty Revenue Related To The Sales Of Future Royalties was Nektar Therapeutics’s largest product and service line in fiscal 2025, bringing in $54.93M of $55.23M (99%).
| Product and Service | FY 2016 | FY 2017 | FY 2017 | FY 2017 | FY 2017 | FY 2018 | FY 2018 | FY 2018 | FY 2018 | FY 2019 | FY 2019 | FY 2020 | FY 2020 | FY 2020 | FY 2021 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License, Collaboration & Other Revenue | $1.91M | $520.00K | $597.00K | $300.00K | ||||||||||||||||
| Nektar-358 | — | — | — | — | ||||||||||||||||
| License | — | — | — | — | ||||||||||||||||
| Non-Cash Royalty Revenue Related To The Sales Of Future Royalties | $69.79M | $68.92M | $64.27M | $54.93M | ||||||||||||||||
| Non-Cash Royalty Revenue Related To Sale Of Future Royalties | — | — | — | — | ||||||||||||||||
| Royalty Revenue | — | — | — | — | ||||||||||||||||
| Product Sales | $20.35M | $20.68M | $33.56M | — | ||||||||||||||||
| Total | $92.06M | $90.12M | $98.43M | $55.23M |
Nektar Therapeutics brought in $55.23M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. Nektar Therapeutics regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $98.43M. Non-Cash Royalty Revenue Related To The Sales Of Future Royalties was the largest at $54.93M (99.5%), ahead of License, Collaboration & Other Revenue at $300.00K (0.5%).
Nektar Therapeutics stopped reporting Product Sales as a separate line after fiscal 2024, when it brought in $33.56M.
Nektar Therapeutics (NKTR) reports its revenue by product and service. In fiscal 2025, Non-Cash Royalty Revenue Related To The Sales Of Future Royalties was its largest product and service line, bringing in $54.93M (99.5% of the total), followed by License, Collaboration & Other Revenue at $300.00K (0.5%).
Non-Cash Royalty Revenue Related To The Sales Of Future Royalties was Nektar Therapeutics' largest product and service line in fiscal 2025, bringing in $54.93M, or 99.5% of the $55.23M total across its two product and service lines.
Every figure comes from Nektar Therapeutics' annual financial filings, as reported. Each line keeps the name Nektar Therapeutics gives it, and years follow its fiscal calendar.
Nektar Therapeutics' revenue by product and service goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.